Budget and Payment Schedule. Payment Schedule. MSK shall invoice [****] of the total annual budget for each year of research detailed under “Total Budget “ on the following page at the beginning of each calendar quarter, except that the first invoice for [****] of the total annual budget for Year I shall be sent immediately upon execution of this Agreement, the second invoice shall follow at the beginning of the following quarter. [****] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. [****] BUDGET CATEGORY YEAR ONE YEAR TWO TOTAL TOTALS [****] [****] [****]
Budget and Payment Schedule. Therefore, the following changes to the Agreement are hereby made:
Budget and Payment Schedule. The following budget represents the anticipated costs and funding for conducting the Scope of Work pursuant to this Task Order. The anticipated dates and amounts of payments is as follows: DATE AMOUNT COMPANY AUTHORIZED SIGNATORY ARIZONA AUTHORIZED SIGNATORY By: ________________________________ By: _______________________________ Name: ______________________________ Name: _____________________________ Title: _______________________________ Title: ______________________________ Date: _______________________________ Date: ______________________________ Email: ______________________________ Phone: ______________________________ AGRICULTURAL CENTER DIRECTOR ACKNOWLEDGEMENT By: _______________________________ Name: _____________________________ Title: ______________________________ Date: ______________________________ PRODUCTION RESPONSIBILITY RESPONSIBILITY Procedures Remarks Project leader Farm FIELD PREP Land Prep Planting Seed cost Cultivations Thinning IRRIGATIONS Sprinklers Labor Water cost Furrow Drip CHEMICALS Fertilizers Insecticides Herbicides Fungicides HARVEST Equipment Labor ADDITIONAL REMARKS: Superintendent /University Ag Center Project Leader ATTACHMENT 2 TO EXHIBIT A [insert legal description or depiction of Site and access – roads and walkways to be used by Company]
Budget and Payment Schedule. 4. Rozpočet a rozpis plateb. Sponsor, either directly or through its designee, will provide the financial support to Institution set out in Attachment A (respectively, the “Budget” and the “Payment Schedule”) for the conduct of the Trial in accordance with the terms of the Protocol and this Agreement. The amounts specified in Attachment A represent Institution’s costs of conducting the Trial. Institution will be responsible for making any and all payments due Trial Staff for their conduct of the Trial (except for any payments to a sub-investigator under a Sub-Investigator Agreement (if any)). All amounts are inclusive of all direct, indirect, overhead and other costs, including laboratory and ancillary service charges, and will remain firm for the duration of the Trial, unless otherwise agreed in writing by the parties. Institution will not directly or indirectly seek or receive compensation from third-party payers for any material, treatment or service that is required by the Protocol and provided or paid for by Sponsor, including, Trial Drug, Trial Subject (as defined in Section 5) screening, infusions, physician and nurse services, and diagnostic tests. Institution acknowledges that, under the Investigator Agreement, Investigator will or may be paid directly by or on behalf of Sponsor for the conduct of Trial-related activities. Institution also acknowledges that, under the Sub- Investigator Agreement, sub- investigator will or may be paid directly by or on behalf of Sponsor for the Zadavatel, buď přímo, nebo prostřednictvím pověřeného zástupce, poskytne Poskytovateli finanční podporu uvedenou v Příloze A (dále jen „Rozpočet“, respektive „Rozpis plateb“) k provádění Klinického hodnocení v souladu s podmínkami Protokolu a této Smlouvy. Částky uvedené v Příloze A představují náklady Poskytovatele na provádění Klinického hodnocení. Poskytovatel bude odpovídat za uskutečnění veškerých plateb náležejících Pracovníkům klinického hodnocení za provádění Klinického hodnocení (kromě případných plateb spoluzkoušejícímu podle Smlouvy se spoluzkoušejícím (byla-li uzavřena)). Veškeré částky zahrnují všechny přímé, nepřímé, režijní a ostatní náklady včetně poplatků za laboratorní a doplňkové služby a budou neměnné po celou dobu trvání Klinického hodnocení, pokud se smluvní strany nedohodnou písemně jinak. Poskytovatel nebude přímo ani nepřímo žádat nebo přijímat náhradu od smluvních plátců třetí strany za jakýkoli materiál, léčbu nebo službu požadovanou Protokolem a p...
Budget and Payment Schedule. SECTION D. SCREENING FAILURE PAYMENTS is hereby amended by deleting the language contained within Section D – SCREENING FAILURE PAYMENTS in its entirety and replacing it with the following: 1. PŘÍLOHA B. ROZPOČET A HARMONOGRAM PLATEB, ODDÍL D - PLATBY ZA NEÚSPĚŠNÝ SCREENING se tímto maže znění oddílu D – PLATBY ZA NEÚSPĚŠNÝ SCREENING a nahrazuje následujícím:
Budget and Payment Schedule. Isis agrees to provide Isis Funding in support of the Pre-Clinical Development under this PCD Program, in accordance with Section 6.1 of the Agreement. Other than Isis Funding and reimbursement by Isis for agreed upon costs and expenses set forth in this PCD Program, KIT will pay any costs required to conduct the Pre-Clinical Development under this PCD Program.
Budget and Payment Schedule. 1.5.1. Exhibit 2 attached is the preliminary budget as presented on December 15/16, 2021. The Artist shall prepare a final budget, which shall include all goods, services, and materials, with such costs itemized, during the Design Development phase and shall present to the Client for approval with any revisions to the Approved Artwork.
Budget and Payment Schedule. Vertex shall pay Company (i) at the rate of * delivered to * upon completion of the Project and Vertex’s confirmation of * receipt of material; (ii) a total of * for the *; and (iii) a total of * for storage of the *. In no event shall the total amount payable by Vertex under parts (i), (ii) and (iii) exceed * without Vertex’s written authorization. * Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. The parties acknowledge that the costs of shipping and handling deliverables is not included in the total amount payable above and will be as mutually agreed by the parties prior to Company’s shipment of material to *. All costs and fees are quoted in US Dollars. Payment terms are net 30 days from Vertex’s receipt of Company’s invoice. Company’s invoice should be sent to: Vertex Pharmaceuticals Incorporated 000 Xxxxxxx Xxxxxx Xxxxxxxxx, XX 00000 XXX Attention: Contracts Management EXECUTED as of the 12th day of January, 2006. ACCEPTED AND AGREED: VERTEX PHARMACEUTICALS INCORPORATED WUXI PHARMATECH CO. LTD. By: By: Name: Name: Title: Title: * Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. *
Budget and Payment Schedule. Vertex shall pay Company * for the synthesis upon completion of the Project and Vertex’s receipt of all Target Compound A synthesized under this Appendix. In no event shall the total amount payable by Vertex for Contract Services under this Appendix exceed * without Vertex’s written authorization, exclusive of shipping and handling charges. All costs and fees are quoted in US Dollars. Payment terms are net 30 days from Vertex’s receipt of Company’s invoice. Company’s invoice should be sent to the attention of Contracts Management at: Vertex Pharmaceuticals Incorporated 000 Xxxxxxx Xxxxxx Xxxxxxxxx, XX 00000 XXX Executed as of the day of March, 2007. ACCEPTED AND AGREED: VERTEX PHARMACEUTICALS INCORPORATED WUXI PHARMATECH CO. LTD. By: By: Name: Name: Title: Title: * Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. ATTACHMENT 1 * [End of Attachment 1] * Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. INCORPORATED 02139-4242 VERTEX PHARMACEUTICALS 000 XXXXXXX XXXXXX • XXXXXXXXX, XX TEL. 000.000.0000 • FAX 617.444-6645 xxxx://xxx.xxxx.xxx May , 2007 Dr. Xx Xx, CEO WuXi PharmaTech Co., LTD. 000 XxXx XxxxxXx Xxxxxxxxxx Free Trade Xxxx Xxxxxxxx, Xxxxx 000000 Re: Appendix (November 13, 2006 –*) (the “November 13th Appendix”), appended to that certain Contract Services Agreement (the “Agreement”) by and among Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (San Diego) LLC and WuXi PharmaTech Co., Ltd. (“WuXi”) dated May 18, 2005, as amended. Dear Xx. Xx: Reference is herein made to the November 13th Appendix to extend the period of time provided for the negotiation of the Supply Agreement and to that end we propose that (a) * as written in the third sentence of Section 10 of the November 13th Appendix be deleted and replaced with * and (b) * as written in the first sentence of the first bullet point of Section 10 of the November 13th Appendix be deleted and replaced with *. Except as provided herein, the November 13th Appendix shall remain unchanged and shall govern the conditions of engagement and the Contract Services to be provided thereunder. All capitalized terms not defined herein shall have the meaning in the Agreement ...
Budget and Payment Schedule. [Each revised Budget should show the following, on one chart: Budget from the original contract, new amounts added or subtracted, and new total budget. This should follow the format of the original contract.] Therefore, the following changes to the Agreement are hereby made: Master Agreement for Clinical Trials Management Services IDENIX PHARMACEUTICALS, Inc.
